Eric Gwynn, MD
Urology · Bluffton, SCNPI 1467586628
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Astellas Pharma US Inc accounts for 67.6% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $13,355 and has fallen 89.3% since, to $1,434 in 2025. Among urology clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 145 payments — averaging $129.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$13K
- Coloplast$2K
- Medtronic$2K
- Olympus America Inc.$635
- Neotract Inc.$399
- Palette Life Sciences, Inc.$233
- plus $1K from 18 others
What the payments were for
- Speaking & faculty fees$10,81058%
- Travel & lodging$2,05011%
- Food & beverage$5,83231%
- Education$790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 16 | $12,693 |
| Coloplast | 49 | $2,287 |
| Medtronic(2 entities) | 35 | $1,523 |
| Olympus America Inc. | 8 | $635 |
| Neotract Inc. | 4 | $399 |
| Palette Life Sciences, Inc. | 1 | $233 |
| Pfizer | 6 | $131 |
| Boston Scientific | 2 | $126 |
| Teleflex LLC | 1 | $117 |
| Ambu Inc. | 1 | $94 |
| Sumitomo Pharma America, Inc. | 3 | $58 |
| Axonics, Inc. | 3 | $58 |
| Blue Earth Diagnostics | 2 | $57 |
| Merck | 2 | $54 |
| AbbVie | 2 | $51 |
| Endo USA, Inc. | 2 | $46 |
| Organogenesis Inc. | 1 | $40 |
| Urogen Pharma, Inc. | 1 | $38 |
| AstraZeneca | 1 | $35 |
| Tolmar, Inc. | 1 | $28 |
| Bayer | 1 | $24 |
| Calyxo, Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $13 |
| Intuitive Surgical | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MYRBETRIQ$12,395
- RESTORELLE$482
- SUPRIS$466
- UroLift$443
- INTERSTIM$324
- iTIND System$259
- rezum Generator$109
- TITAN$103
How this compares
$18,770 in reported general payments places this provider in the 90th percentile of 196 urology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 47 | $57,035 |
| GemtesaVibegron | 38 | $33,413 |
| Tamsulosin Hcl | 140 | $2,076 |
| Trimethoprim | 16 | $1,576 |
| Solifenacin Succinate | 29 | $1,399 |
| Oxybutynin Chloride ErOxybutynin Chloride | 54 | $1,334 |
| Potassium Citrate ErPotassium Citrate | 14 | $1,305 |
| Dutasteride | 26 | $1,090 |
| Finasteride | 53 | $821 |
| Ciprofloxacin Hcl | 165 | $757 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 156 | $638 |
| Bicalutamide | 16 | $486 |
| Testosterone | 19 | $362 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 124 | $239 |
| Cefdinir | 11 | $225 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $12,693 | $57,03547 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $58 | $33,41338 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 196 urology providers in South Carolina.
Other urology in Bluffton
- Neal ShoreMyrtle Beach$3.2M
- Manish PatelElgin$213K
- Sandip PrasadCharleston$177K
- Benjamin DropkinGreenville$65K
- Ian MarshallCharleston$60K
- Elizabeth BozemanFlorence$57K
- Thomas KeaneCharleston$52K
- Abhishek SrivastavaMyrtle Beach$41K
- William BogacheMyrtle Beach$41K
- Christopher BallantyneGreenville$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.